Targeting “writers” such as METTL3 or METTL14 blocks the formation of m6A and thus can play a role in multiple tumor-suppressing or immune therapy-enhancing effects; however, this may also greatly impact normal physiological functions and lead to severe side effects. The gene discussed is METTL14; the disease is neoplasm.